862081-37-6

Basic information

• Product Name: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isobenzofuran-1(3H)-one
• Synonyms: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isobenzofuran-1(3H)-one;5-(Tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-dihydro-2-benzofuran-1-one;5-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-Yl)Isobenzofuran-1(3H)-One(WX652032);(1-OXO-1,3-DIHYDROISOBENZOFURAN-5-YL)BORONIC ACID PINACOL ESTER
• CAS NO: 862081-37-6
• Molecular Formula: C₁₄H₁₇BO₄
• Molecular Weight: 260.1
• Mol File: 862081-37-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isobenzofuran-1(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isobenzofuran-1(3H)-one(862081-37-6)
• EPA Substance Registry System: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isobenzofuran-1(3H)-one(862081-37-6)

Safety Data

• Hazardous Substances Data: 862081-37-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isobenzofuran-1(3H)-one is used as a key intermediate in the synthesis of bioactive molecules for pharmaceutical applications. Its unique structure allows for the development of compounds with specific biological activities, making it a valuable tool in medicinal chemistry.
Used in the Design of Perforin Inhibitors:
In the field of immunology, 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isobenzofuran-1(3H)-one is utilized in the design and discovery of inhibitors targeting the lymphocyte pore-forming protein perforin. These inhibitors are crucial for understanding the role of perforin in immune responses and could potentially lead to the development of therapies for autoimmune diseases and other conditions where perforin-mediated cytotoxicity is implicated.
Used in Chemical Synthesis:
Due to its reactivity and stability, 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isobenzofuran-1(3H)-one is also used in various chemical synthesis processes. It can serve as a building block for the creation of more complex organic molecules, including those with potential applications in materials science, agrochemicals, and other industries.
Used in Academic Research:
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isobenzofuran-1(3H)-one is a subject of interest in academic research, where it is studied for its chemical properties, reactivity, and potential applications in various fields. Researchers use 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isobenzofuran-1(3H)-one to explore new synthetic routes, reaction mechanisms, and the development of novel catalysts and methodologies in organic chemistry.

Upstream product

• 64169-34-2 5-bromophthalide 
• 126726-62-3 2-isopropenyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane 
• 19477-73-7 6-bromophthalide 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1374263-45-2 tert-butyl (1-{4-[2-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)-9H-imidazo[1,2-d]pyrido[2,3-b][1,4]benzodiazepin-3-yl]phenyl}cyclobutyl)carbamate 
• 1374261-51-4 5-{3-[4-(1-aminocyclobutyl)phenyl]-9H-imidazo[1,2-d]pyrido[2,3-b][1,4]benzodiazepin-2-yl}-2-benzofuran-1(3H)-one 
• 1313397-93-1 5-(3-(dimethoxymethyl)phenyl)isobenzofuran-1(3H)-one 
• 1359020-76-0 5-(2-(dimethoxymethyl)phenyl)isobenzofuran-1(3H)-one 
• 1313397-95-3 5-(4-(dimethoxymethyl)phenyl)isobenzofuran-1(3H)-one 
• 1359020-88-4 2-(5-(1-oxo-1,3-dihydroisobenzofuran-5-yl)thiophen-2-yl)acetic acid 
• 1313397-11-3 (E,Z)-5-(4-(1-oxo-1,3-dihydroisobenzofuran-5-yl)benzylidene)-2-thioxoimidazolidin-4-one 
• 1313397-96-4 4-(1-oxo-1,3-dihydroisobenzofuran-5-yl)benzaldehyde 
• 1313397-10-2 (E,Z)-5-(3-(1-oxo-1,3-dihydroisobenzofuran-5-yl)benzylidene)-2-thioxoimidazolidin-4-one 
• 1359020-82-8 (E,Z)-1-(4-methoxybenzyl)-3-((5-(1-oxo-1,3-dihydroisobenzofuran-5-yl)thiophen-2-yl)methylene)piperidin-2-one 

Relevant articles and documents

Discovery and Early Clinical Development of Isobutyl 1-[8-Methoxy-5-(1-oxo-3 H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5- a]pyridin-2-yl]cyclopropanecarboxylate (LEO 39652), a Novel "dual-Soft" PDE4 Inhibitor for Topical Treatment of Atopic Dermatitis

We describe the design of a novel PDE4 scaffold and the exploration of the dual-soft concept to reduce systemic side effects via rapid elimination: introducing ester functionalities that can be inactivated in blood as well as by the liver (dual-soft) while being stable in human skin. Compound 40 was selected as a clinical candidate as it was potent and rapidly degraded by blood and liver to inactive metabolites and because in preclinical studies it showed high exposure at the target organ: the skin. Preclinical and clinical data are presented confirming the value of the dual-soft concept in reducing systemic exposure.

NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS

The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

no abstract published

TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS

The present invention is directed to tricyclic compounds (I), pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

METHODS FOR THE PREPARATION OF SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIDINES

The present invention relates to novel methods for the preparation of substituted [1,2,4]triazolo[1,5-a]pyridinesand intermediates for the same. The compounds are useful as PDE4 inhibitors.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kirl.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure

RORGAMMAT INHIBITORS

The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition.

PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS

JAK1 inhibitors of structural formula (I), wherein Ar1, Ar2, Q, W, X, Y, and Z are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds

The present invention relates to substituted benzo-imidazo-pyrido-diazepine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted benzo-imidazo-pyrido-diazepine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.